RUNX1 and myelodysplastic syndrome: MDS patients with RUNX1 mutations respond poorly to chemotherapeutic regimens, and the mechanism may involve multiple aspects affecting cell proliferation and differentiation, DNA damage and repair defects, apoptotic processes, and signaling pathways (58, 59).